siRNA – AN EXCELLENT TECHNIQUE FOR DOWNREGULATION OF GENE EXPRESSION (original) (raw)

RNA interference (RNAi) was originally described in the nematode worm Caenorhabditis elegans as a response to double-stranded RNA (dsRNA), in which target mRNAs are degraded in a sequence-specific manner. Short sermon molecules can be prepared by direct chemical synthesis or transcription driven by RNA polymerase promoters. After recent discovery the use of small interfering RNA (siRNA) has become a powerful tool in silencing highly over expressed oncogenes in cancer. Now siRNA technology holds promise as a novel therapeutic modality for targeted silencing of cancer genes especially for those proteins that cannot be targeted by small inhibitors. However, clinical applications of siRNA-based therapeutics relay on the successful delivery of primary and metastatic tumors and remains as a great challenge. Designing and then chemically stabilizing the siRNA and can stabilize and improve the drug properties of siRNA therapeutics by using specific chemical modifications. A chemogenomics approach towards novel target discovery combined with RNAi-based screening is facilitating the robust, improved discovery of new targeted therapies. These approaches have strong potential to provide better cancer drug targets using a combination of short interfering RNA (siRNA) libraries and pre-existing chemotherapies, as well as a combination of siRNAs and novel compound libraries. RNAi is one of the most recent discoveries of a naturally occurring mechanism of gene regulation that is triggered by the introduction of double-stranded RNA into a cell. Designed to specifically knock down the expression of genes harboring a particular target sequence, and they represent an exciting therapeutic potential for inhibiting gene expression